MD Anderson and Generate: Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

Misetionamide, a tumor cell-selective small molecule drug that is broadly active in multiple cancer models, demonstrated excellent monotherapy results as well as synergistic activity with PARP inhibitors and bevacizumab antineoplastic in ovarian cancer in a recent preclinical study.

September 06, 2024

Vol.50 No.33

In Brief

MD Anderson and industry partners to conduct T cell studies on the International Space Station

The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station to study the effects of prolonged microgravity on cell differentiation, activation, memory, and exhaustion.

August 02, 2024

Vol.50 No.31

In Brief

MD Anderson, Rice form Cancer Bioengineering Collaborative

The University of Texas MD Anderson Cancer Center and Rice University formed the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis, and treatment.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Upregulating TERT gene expression reverses multiple hallmarks of aging

Researchers at MD Anderson Cancer Center have demonstrated that therapeutically restoring ‘youthful’ levels of a specific subunit of the telomerase enzyme can significantly reduce the signs and symptoms of aging in preclinical models.

June 28, 2024

Vol.50 No.26

In Brief

MD Anderson’s Institute for Data Science in Oncology establishes internal advisory council

The Institute for Data Science in Oncology at MD Anderson Cancer Center has established an internal advisory council to identify needs and opportunities for data science development and integration across MD Anderson, advancing work that will yield significant benefits for patients and families.

June 21, 2024

Vol.50 No.25

Clinical Roundup

CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity

Adding CD28 costimulation to cord blood-derived chimeric antigen receptor natural killer cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from MD Anderson Cancer Center.

June 21, 2024

Vol.50 No.25

MD Anderson and Generate: Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI

YOU MAY BE INTERESTED IN

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

MD Anderson and industry partners to conduct T cell studies on the International Space Station

MD Anderson, Rice form Cancer Bioengineering Collaborative

Upregulating TERT gene expression reverses multiple hallmarks of aging

MD Anderson’s Institute for Data Science in Oncology establishes internal advisory council

CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login